Search research articles
Contact Us
Filters
Showing results (51-60 of 119) with videos related to
Page
of 12
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
September 13, 2015
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Syed M Kazmi, Maliha Nusrat, Hilal Gunaydin, et al.
Bone Marrow Transplantation
|
October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
Mithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer
|
September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma
Idrees Mian, Denái R Milton, Nina Shah, et al.
American Journal of Hematology
|
August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experience
Prajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
Yago Nieto, Uday Popat, Paolo Anderlini, et al.
American Journal of Hematology
|
January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
Elias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
Cancer
|
September 3, 2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
Manish Sharma, Hassan Khan, Peter F Thall, et al.
NEJM Evidence
|
April 22, 2025
Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS
Neil A Shneider, Alex V Nesta, Olivia M Rifai, et al.
Blood
|
August 31, 2006
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
Tony A Navas, Mani Mohindru, Myka Estes, et al.
British Journal of Haematology
|
January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
Fleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 119) with videos related to
Sort By:
Page
of 12
Clinical Lymphoma, Myeloma & Leukemia
|
September 13, 2015
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Syed M Kazmi, Maliha Nusrat, Hilal Gunaydin, et al.
Bone Marrow Transplantation
|
October 20, 2018
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation
Mithun Vinod Shah, Rima M Saliba, Gabriela Rondon, et al.
Cancer
|
September 30, 2016
Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma
Idrees Mian, Denái R Milton, Nina Shah, et al.
American Journal of Hematology
|
August 30, 2017
Clinical outcomes in adult patients with aplastic anemia: A single institution experience
Prajwal Boddu, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
November 7, 2012
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome
Yago Nieto, Uday Popat, Paolo Anderlini, et al.
American Journal of Hematology
|
January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
Elias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
Cancer
|
September 3, 2011
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
Manish Sharma, Hassan Khan, Peter F Thall, et al.
NEJM Evidence
|
April 22, 2025
Clinical Safety and Preliminary Efficacy of Regulatory T Cells for ALS
Neil A Shneider, Alex V Nesta, Olivia M Rifai, et al.
Blood
|
August 31, 2006
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
Tony A Navas, Mani Mohindru, Myka Estes, et al.
British Journal of Haematology
|
January 22, 2013
Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation
Fleur M Aung, Benjamin Lichtiger, Roland Bassett, et al.
Page
of 12